Overview

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Phase:
Phase 3
Details
Lead Sponsor:
Stanford University
Treatments:
Anti-Infective Agents
Vancomycin